Tempus AI and Bristol Myers Squibb Expand AI Clinical Trial Partnership
CHICAGO, Illinois, May 2026 Tempus AI announced an expanded strategic collaboration with Bristol Myers Squibb aimed at improving the...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
CHICAGO, Illinois, May 2026 Tempus AI announced an expanded strategic collaboration with Bristol Myers Squibb aimed at improving the...
CULVER CITY, Calif. – May 5, 2026 ImmunityBio Inc. has announced it will present new comparative clinical data and...
SAN DIEGO, April 7, 2026 Phanes Therapeutics, Inc. has announced the initiation of the dose expansion phase in its...
Hong Kong, April 6, 2026 Promising Results in Immunotherapy-Resistant NSCLC In a significant advancement for lung cancer immunotherapy, Akeso,...
San Diego, USA & Suzhou, China, April 2, 2026 Breakthrough Collaboration in Immuno-Oncology In a significant step forward for...
BASEL, Switzerland, Sept. 26, 2025 — Novartis announced it will present 34 abstracts from its oncology pipeline at the...
